About > Pharmaceutical Companies

The JEC seeks to develop good working relationships with pharmaceutical companies interested in the field of epilepsy. It recognises that people with epilepsy will be the beneficiaries of new anti-epileptic medications so the JEC has a duty to represent their interests in an independent and impartial manner. There is no promotion of one anti-epileptic drug over another by the JEC. Neither is it the JEC's role to promote drug based therapies in preference to alternative strategies. The JEC believes that in an ideal world everyone with epilepsy should have access to all strategies that may help to improve seizure control.

The JEC does not have independent sources of funding over and above its membership subscriptions, so it actively encourages pharmaceutical companies to become corporate supporters of the JEC through the payment of an annual donation.

The JEC reserves the right to comment publicly when anyone, including any pharmaceutical company, is not acting in the best interest of people with epilepsy. However it would only do this after consultation with the individual or organisation in question.

JEC recognizes that many of its members have active and mutually beneficial relationships with pharmaceutical companies, and is fully supportive of this. Like its member organizations, the JEC would not compromise its independence by accepting financial support from any individual or organisation which it believes is not acting in the best interests of people with epilepsy.

JEC acknowledges the support it has received from:
EISAI
Pfizer Global Pharmaceuticals
Sanofi-Aventis
UCB Pharma Limited